Cereno Scientific AB: Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides add...
Finanznachrichten.de
via Finanznachrichten.de
Updated 3h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Bloodhounds 2 review: Woo Do-hwan's show lands like a clean, decisive knockout
Next
This is how luxury hotels get their bed sheets crisp, white and smelling fresh — and the secret is in your cabinets, expert says
Related Articles
BusinessIndia to unlock Southeast Asia's USD 90 billion AgriTech growth potential: Study
Timesofoman-16h ago-1 sources
BusinessMicron Stock Could Be The Next Intel (NASDAQ:MU)
Seeking Alpha-16h ago-1 sources
BusinessIranian Strike on U.S. Embassy Caused More Damage Than Disclosed (Wall Street Journal)
Memeorandum-21h ago-1 sources